Overview
Ratio Therapeutics is a biopharmaceutical company developing targeted radiotherapeutics, with work focused on moving its pipeline through clinical development. Its products are aimed at healthcare providers and patients served by precision nuclear medicine and radiopharmaceutical treatment approaches. The company’s stated near-term priorities are advancing clinical programs and expanding manufacturing, suggesting differentiation around both therapeutic targeting and production capacity. Ratio Therapeutics raised $70 million in a July 2026 Series C financing to support those efforts, bringing disclosed funding in the provided context to $70 million.
Funding History
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturi
Frequently Asked Questions
- How much has Ratio Therapeutics raised in total?
- Ratio Therapeutics has raised a total of $70M across 1 funding round.
- What does Ratio Therapeutics do?
- Ratio Therapeutics is a biopharmaceutical company developing targeted radiotherapeutics, with work focused on moving its pipeline through clinical development. Its products are aimed at healthcare providers and patients served by precision nuclear medicine and radiopharmaceutical treatment approaches. The company’s stated near-term priorities are advancing clinical programs and expanding manufacturing, suggesting differentiation around both therapeutic targeting and production capacity. Ratio Therapeutics raised $70 million in a July 2026 Series C financing to support those efforts, bringing disclosed funding in the provided context to $70 million.
- Where is Ratio Therapeutics headquartered?
- Ratio Therapeutics is headquartered in Boston, United States.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.